Best Practices in Lung Cancer – November 2017 Vol 8
In this Special Edition, we direct our attention to lung cancer and the positive impact navigators have had in this disease state.
In an effort to understand a day in the life of a thoracic navigator, we spent some time with Wendy Brooks, RN, ONN-CG. Ms Brooks obtained her certification as generalist oncology nurse navigator through the Academy of Oncology Nurse & Patient Navigators (AONN+) and was instrumental in the development of the AONN+ specialty certification exam in thoracic oncology.
To be effective, navigators are required to stay up to date on the constantly changing landscape of lung cancer care.
Academy of Oncology Nurse & Patient Navigators and the American Cancer Society (ACS) Forge Partnership
It has been proved that teamwork is vital in the battle against cancer. This is a fact that the Academy of Oncology Nurse & Patient Navigators (AONN+) and the American Cancer Society (ACS) recently validated when they entered into a National Alliance Partnership Program.
Osimertinib improves progression-free survival by 54% compared with standard first-line therapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC), according to late-breaking results from the FLAURA trial presented at the ESMO 2017 Congress in Madrid.
Durvalumab, a PD-L1 inhibitor, improved progression-free survival (PFS) by 11.2 months compared with placebo in patients with locally advanced, unresectable stage III non–small cell lung cancer (NSCLC) that did not progress after standard treatment with chemoradiotherapy, according to results presented at the ESMO 2017 Congress.
Findings of a randomized study suggest that follow-up CT scans may not be needed every 3 to 6 months during the first 2 years after surgery for patients with non–small cell lung cancer (NSCLC).
Results 1 - 7 of 7